Overview

A Single Ascending Dose Study to Characterize the Pharmacokinetics, Safety, and Tolerability of SAR441566 in Healthy Adult Japanese Male Participants.

Status:
Not yet recruiting
Trial end date:
2023-07-03
Target enrollment:
Participant gender:
Summary
This is a cross-over, Phase 1, 3-treatment period single sequence study. The purpose of this study is to characterize pharmacokinetics (PK), safety, and tolerability of single ascending oral doses of SAR441566 in healthy male Japanese participants, 18-55 years of age.
Phase:
Phase 1
Details
Lead Sponsor:
Sanofi